Home / Market News / $QNRX
benzinga Corporate Catalyst Impact 75/100 ● neutral

Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome

Oct 20, 2026, 10:36 AM UTC · Primary ticker $QNRX

Quoin Pharma announced the publication of a peer-reviewed paper detailing positive compassionate use data for its QRX003 treatment for Netherton Syndrome, showing significant improvement in a pediatric patient. This news, coupled with previously reported positive interim Phase 2/3 data and a clear timeline for future results, provides a strong positive catalyst for the company's stock.

Quoin Pharma has published a peer-reviewed paper on QRX003, highlighting its mechanism of action and, crucially, a case report of a pediatric patient with Netherton Syndrome who experienced significant and sustained improvement (from severe to clear skin, complete elimination of itch) over 21 months of compassionate use, with no adverse events. This positive clinical data, especially in a rare and severe condition, validates the drug's potential and builds on previously reported positive interim Phase 2/3 results. For traders, this provides a strong short-term positive catalyst for QNRX, as it de-risks the drug and increases confidence in its eventual approval. The long-term implication is a potentially lucrative market for Quoin if QRX003 successfully navigates clinical trials and regulatory approval, given the unmet medical need in Netherton Syndrome. The key opportunity is the continued positive momentum leading up to the Phase 2/3 topline data in Q2 2027.

$QNRX positive Positive clinical data and publication for lead drug candidate
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.